Suchergebnisse - "Wang, Chin-Chou"

PubPharm (196)

41

Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue

enthalten in: Thoracic Cancer | 2022

von Wang, C. | Huang, K. | Chang, H. | +6

42

A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy

enthalten in: Oncology and therapy | 2021

von Wang, C. | Chiu, L. | Tung, P. | +7

43

Comparing survival and treatment response of patients with acquired T790M mutation second-line osimertinib versus sequential treatment of chemotherapy followed by osimertinib : A real-world study

enthalten in: Thoracic cancer | 2021

von Wang, C. | Lai, C. | Chang, Y. | +4

44

The Risk Factors of Blood Cadmium Elevation in Chronic Kidney Disease

enthalten in: International journal of environmental research and public health | 2021

von Tsai, K. | Hsu, P. | Kung, C. | +7

45

Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients : A Focus on EGFR Mutation

enthalten in: Nutrients | 2021

von Chen, Y. | Lai, C. | Lin, C. | +11

46

Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients : A Multicenter Observational Study

enthalten in: Vaccines | 2021

von Wang, C. | Chiu, L. | Ju, J. | +4

47

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

enthalten in: JTO clinical and research reports | 2021

von Park, K. | Tan, D. | Su, W. | +10

48

Application of a 72 h National Early Warning Score and Incorporation with Sequential Organ Failure Assessment for Predicting Sepsis Outcomes and Risk Stratification in an Intensive Care Unit : A Derivation and Validation Cohort Study

enthalten in: Journal of personalized medicine | 2021

von Hsu, C. | Tsai, Y. | Lin, C. | +9

49

Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2021

von Su, P. | Tsai, J. | Yang, S. | +9

50

METHOD FOR DIAGNOSING AND TREATING ASTHMA BY DETECTING OR REGULATING A PANEL OF INTERNAL LIPID SPECIES

enthalten in: Europäisches Patentamt | 2021

von HUANG SHAU-KU | HUANG MING-SHYAN | WANG CHIN-CHOU | +2